EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 94 filers reported holding EPIZYME INC in Q4 2016. The put-call ratio across all filers is 3.03 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $14,000 | -67.4% | 11,791 | -31.0% | 0.00% | – |
| Q4 2021 | $43,000 | -79.1% | 17,092 | -57.6% | 0.00% | -100.0% |
| Q3 2021 | $206,000 | +27.2% | 40,286 | +117.0% | 0.00% | 0.0% |
| Q1 2021 | $162,000 | -6.4% | 18,567 | +16.8% | 0.00% | 0.0% |
| Q4 2020 | $173,000 | -73.6% | 15,892 | -71.1% | 0.00% | -75.0% |
| Q3 2020 | $655,000 | +261.9% | 54,895 | +387.7% | 0.00% | +100.0% |
| Q2 2020 | $181,000 | -23.9% | 11,256 | -26.7% | 0.00% | 0.0% |
| Q1 2020 | $238,000 | -7.0% | 15,349 | +47.3% | 0.00% | 0.0% |
| Q4 2019 | $256,000 | +42.2% | 10,420 | -28.1% | 0.00% | 0.0% |
| Q1 2019 | $180,000 | -13.9% | 14,500 | +32.2% | 0.00% | 0.0% |
| Q3 2017 | $209,000 | +3.5% | 10,966 | -17.9% | 0.00% | 0.0% |
| Q2 2017 | $202,000 | +61.6% | 13,364 | +83.3% | 0.00% | +100.0% |
| Q1 2017 | $125,000 | -49.6% | 7,292 | -64.4% | 0.00% | -50.0% |
| Q4 2016 | $248,000 | +71.0% | 20,480 | +166.1% | 0.00% | +100.0% |
| Q1 2015 | $145,000 | -54.3% | 7,696 | -44.7% | 0.00% | 0.0% |
| Q1 2014 | $317,000 | – | 13,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |